This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.
A new report from the American Economic Liberties Project presents the continued challenges pharmacies face since Congress failure to pass PBM reform at the end of 2024.
LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.
In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers assessed state-level regulations for PBMs.
Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.
Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.
In a session presented at the 2024 Heart in Diabetes Conference, Matthew Weir, MD, discussed the potential benefits of GLP-1s and SGLT2 inhibitors for improved chronic kidney disease and cardiovascular outcomes.
In 4 posters presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024, researchers addressed pharmacists’ role in managing patients’ anticancer medications.
At ADA 2024, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.
Research presented at Digestive Disease Week suggests that including omega-3 rich foods, or omega-3 supplements, into a healthy diet could offer additional protection against colorectal cancer alongside regular screening.
Presenters at the National Community Pharmacists Association 2024 Annual Convention and Expo discussed workflow and the future of pharmacy as a patient destination.
An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.
Three posters being presented at the Society for Maternal-Fetal Medicine 44th Annual Pregnancy Meeting examined the impact of continuous glucose monitoring on pregnancy outcomes.
In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers addressed continuous glucose monitoring and its potential role in indigent communities.
Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.
Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.
Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.
In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.
Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.
History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.
At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with T1D are at high risk for developing anorexia and bulimia.
Four abstracts presented at ASCO 2024 delved into cannabis and pain management, potential medication interactions, and symptom mitigation, in patients with cancer.
Mehrdad Hariri, RPh, CPh, MBA presented a session at July's Total Pharmacy Solution Summit on all the ways you can leverage those data for success. How many different ways can analytics assist your pharmacy? More than you may think.
Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.
Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.
Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.
Research presented at ENDO 2024 found that glucagon-like peptide-1 receptor agonists had a lower acute pancreatitis recurrence risk than SGLT2i, DPP4i, and no medication.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content